Patients were randomized to receive ipilimumab , 10 mg/kg , intravenously on day 1 plus sargramostim , 250 g subcutaneously , on days 1 to 14 of a 21-day cycle ( n = 123 ) vs ipilimumab alone ( n = 122 ) .